全球首个CD47单抗实体瘤III期临床首例入组:依沃西联合莱法利一线治疗HNSCC(对比帕博利珠单抗) Ivonescimab+AK117 近日,康方生物(9926.HK)宣布其自主研发的全球首创的PD-1/VEGF双特异性抗体依沃西联合新一代D47单抗莱法利(AK117)对比帕博利珠单抗一线治疗PD-L1阳性(CPS≥1)复发转移性头颈部鳞癌(R/M HNSCC)随机、对...
DRUG efficacyPatients with gastric cancer liver metastasis (GCLM) are often treated with palliative care, and they show a poor prognosis. In gastric cancer, high CD47 expression has been shown to indicate a poor prognosis. CD47, expressed on the cell surface, prevents the cells from ...
Interaction of CD47 and signal regulatory protein-α (SIRPα) delivers an antiphagocytic ‘don't eat me’ signal to promote tumor cell evasion from macrophages. CC-90002 is a humanized IgG4-PE CD47 antibody that inhibits CD47-SIRPα interaction and enabled phagocytosis across a panel of cancer...
Cancer Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed February 6, 2025 · 2 min read · Tristan Manalac Parkinson’s disease Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo ...
Incubation of NHL cells in the presence of IgG1 isotype control or anti-CD45 IgG1 antibody did not result in significant phagocytosis; however, two different blocking anti-CD47 antibodies (B6H12.2 and BRIC126) enabled phagocytosis of NHL cells but not NPB cells (Figures 2A and 2B). Download...
Anti-SIRPα Antibody (Biosion): 一种SIRPα抑制剂药物,由Biosion, Inc. (博奥信生物技术(南京)有限公司)公司最早进行研发,目前全球最高研发状态为终止,作用机制: SIRPα抑制剂(信号调节蛋白α抑制剂),治疗领域: 肿瘤,皮肤和肌肉骨骼疾病。
Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer A novel injectable double-layer-gel matrix is developed. The hierarchically structured dual lipid gel matrix enables time-programmed drug delivery....
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103–11108 (2013). CAS PubMed PubMed Central Google Scholar Pardoll, D. Cancer and the immune system: basic concepts and targets for intervention...
However, the use of Darzalex poses challenges in pre-transfusion testing due to its strong binding affinity of the monoclonal anti-CD38 antibody to CD38 ... A Dilberovi,L Kola,I Kola - 《Journal of Health Sciences》 被引量: 0发表: 2023年 Antibodies for Bioanalysis and Drug Monitoring of ...
CD47 antibody blocks this signal and enables macrophages to attack tumor cells, making it a potentially promising cancer drug. However, development of CD47 antibody as a cancer therapy is hampered by its hematologic side effects, such as severe anemia, caused by natural binding...